Head to head
Quest Diagnostics vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: DGX · TMO
DGX
Quest Diagnostics
227.06-0.58%
1-year price shape — +26% over the period
Quant Rating B · 70/100
vs
TMO
Thermo Fisher Scientific
662.06+0.83%
1-year price shape — +23% over the period
Quant Rating C · 64/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific earns the most per share.
| DGX | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 227.06 | 662.06 |
| Change today | -0.58% | +0.83% |
| 1-year return | +26.5% | +23.1% |
| Market cap | $25.06B | $244.79B |
| 52-week range | 168.34 – 247.92 | 434.50 – 694.33 |
| Valuation | ||
| P/E (TTM) | 24.10 | 35.63 |
| P/E percentile, own 5-yr range | 97th | 86th |
| P/B | 3.33 | 4.65 |
| Dividend yield | 1.08% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 8.75 | 17.74 |
| Net profit (TTM) | $965.77M | $6.56B |
| Revenue (TTM) | $11.56B | $46.34B |
| Revenue growth (YoY) | +10.2% | +10.5% |
| Gross margin | 33.1% | 40.8% |
| Operating margin | 14.1% | 18.3% |
| Net margin | 9.2% | 15.0% |
| Free cash flow (TTM) | $1.35B | $7.32B |
| Ownership & sentiment | ||
| Institutional ownership | 97.5% | 93.1% |
| Insider activity (12mo) | 35 buy / 15 sell | 22 buy / 28 sell |
| Short interest (% of float) | 3.3% | 1.4% |
| Analyst consensus | 64% buy / 36% hold (11) | 88% buy / 12% hold (17) |
| Analyst price target | $255 (+12%) | $653 (-1%) |
| StockVane view | ||
| StockVane Quant Rating | B (70) | C (64) |
| Company | ||
| Employees | 57,000 | 125,000 |
| Founded | 1967 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.